Anavex Life Sciences Corp (AVXL)

[12x]

Wonder if this capital raise takes the MAA withdrawal option off the table.

Missling seems to have structured this as a win-win from a management perspective — with the only real drawback being the loss of the withdrawal option:

-Worst-case: Follow the Pridopidine playbook — take it all the way to CHMP refusal, but raise $150M in survival capital along the way (as done in 2021).
-Mid-case: Use the funds to run a confirmatory trial if conditional approval is granted.
-Best-case: Deploy the capital for go-to-market execution following full approval.

The speed/price at which the company taps this ATM will reveal how confident management really is in the MAA outcome.